CAPONE, EMILY
 Distribuzione geografica
Continente #
NA - Nord America 697
EU - Europa 554
AS - Asia 165
AF - Africa 1
Continente sconosciuto - Info sul continente non disponibili 1
SA - Sud America 1
Totale 1.419
Nazione #
US - Stati Uniti d'America 697
IT - Italia 180
IE - Irlanda 157
SE - Svezia 86
CN - Cina 72
FR - Francia 35
TR - Turchia 35
UA - Ucraina 32
IN - India 25
DE - Germania 23
VN - Vietnam 22
GB - Regno Unito 20
BE - Belgio 8
FI - Finlandia 5
GR - Grecia 4
CH - Svizzera 2
HK - Hong Kong 2
TW - Taiwan 2
AE - Emirati Arabi Uniti 1
AR - Argentina 1
EG - Egitto 1
EU - Europa 1
IL - Israele 1
JP - Giappone 1
KR - Corea 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
MY - Malesia 1
PK - Pakistan 1
RO - Romania 1
Totale 1.419
Città #
Chandler 207
Dublin 155
Jacksonville 71
Princeton 53
Ann Arbor 43
Chieti 41
Ashburn 35
Altamura 27
Dong Ket 22
Beijing 21
Dearborn 20
Izmir 18
Nanjing 18
Wilmington 18
Los Angeles 12
New York 12
Boardman 9
Pune 9
Brussels 8
Southend 8
Cambridge 7
Falls Church 7
Hebei 7
Milan 7
Finale Ligure 5
Nanchang 5
Norwalk 5
Pescara 5
Washington 5
Collecorvino 4
Putignano 4
Redwood City 4
Seattle 4
Woodbridge 4
L'aquila 3
Mcallen 3
Tappahannock 3
Andover 2
Cattolica 2
Changsha 2
Chicago 2
Civitanova Marche 2
Dübendorf 2
Fairfield 2
Hefei 2
Hong Kong 2
Kunming 2
Leinì 2
L’Aquila 2
Montesilvano Marina 2
Munich 2
Ningbo 2
San Salvo 2
Shenyang 2
Spoltore 2
Stockholm 2
Taipei 2
Tianjin 2
Vezzano sul Crostolo 2
Zhengzhou 2
Ancona 1
Ardea 1
Atlanta 1
Brescia 1
Buenos Aires 1
Busso 1
Cairo 1
Changchun 1
Cislago 1
Clearwater 1
Cluj-napoca 1
Corridonia 1
Dubai 1
Edinburgh 1
Fuzhou 1
Grevenbroich 1
Gwanak-gu 1
Imola 1
Issy-les-moulineaux 1
Istanbul 1
Jinan 1
Jülich 1
Lappeenranta 1
London 1
Luxembourg 1
Marcallo Con Casone 1
Messina 1
Napoli 1
Nuremberg 1
Orsogna 1
Petaling Jaya 1
Phoenix 1
Rome 1
San Jose 1
San Vito Chietino 1
Sansepolcro 1
Scafa 1
Shijiazhuang 1
Shizuoka 1
Silvi 1
Totale 975
Nome #
miR-205-5p-mediated downregulation of ErbB/HER receptors in breast cancer stem cells results in targeted therapy resistance 112
EV20-mediated delivery of cytotoxic auristatin MMAF exhibits potent therapeutic efficacy in cutaneous melanoma 91
EV20-Sap, a novel anti-HER-3 antibody-drug conjugate, displays promising antitumor activity in melanoma 91
Secreted Gal-3BP is a novel promising target for non-internalizing Antibody–Drug Conjugates 88
ErbB-3 activation by NRG-1β sustains growth and promotes vemurafenib resistance in BRAF-V600E colon cancer stem cells (CSCs) 83
Dual targeting of ErbB-2/ErbB-3 results in enhanced antitumor activity in preclinical models of pancreatic cancer. 77
Repurposing a psychoactive drug for children with cancer: p27 Kip1-dependent inhibition of metastatic neuroblastomas by Prozac 73
Pharmacological inhibition of ABCC3 slows tumour progression in animal models of pancreatic cancer 66
Generation of a novel Antibody-Drug Conjugate targeting endosialin: potent and durable antitumor response in sarcoma 65
ABCC3 is a novel target for the treatment of pancreatic cancer 65
Normal breathing releases SARS-CoV-2 into the air 59
EV20, a Novel Anti-ErbB-3 Humanized Antibody, Promotes ErbB-3 Down-Regulation and Inhibits Tumor Growth In Vivo. 58
HER3 targeting with an antibody-drug conjugate bypasses resistance to anti-HER2 therapies 56
LGALS3BP antibody-drug-conjugate and its use for the treatment of cancer 56
Preclinical validation of 3-phosphoinositide-dependent protein kinase 1 inhibition in pancreatic cancer 52
Targeting vesicular lgals3bp by an antibody-drug conjugate as novel therapeutic strategy for neuroblastoma 49
Antibody-drug conjugates: The new frontier of chemotherapy 48
EV20‑sss‑vc/MMAF, an HER‑3 targeting antibody‑drug conjugate displays antitumor activity in liver cancer 47
HER-3: Hub for escape mechanisms 45
Dual PDK1/aurora kinase a inhibitors reduce pancreatic cancer cell proliferation and colony formation 45
BAG3 induces fibroblasts to release key cytokines involved in pancreatic cell migration 41
EV20/NMS-P945, a Novel Thienoindole Based Antibody-Drug Conjugate Targeting HER-3 for Solid Tumors 33
HPLC-DAD validated method for DM4 and its metabolite S-Me-DM4 quantification in biological matrix for clinical and pharmaceutical applications 29
Endosialin-binding antibody 27
MYC regulates metabolism through vesicular transfer of glycolytic kinases 25
Extracellular LGALS3BP: a potential disease marker and actionable target for antibody-drug conjugate therapy in glioblastoma 17
Therapeutic potential of antibody‐drug conjugate‐based therapy in head and neck cancer: A systematic review 14
Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans 14
Visualizing Galectin-3 Binding Protein Expression with ImmunoPET 13
Role of galectin 3 binding protein in cancer progression: a potential novel therapeutic target 10
HER-3 surface expression increases in advanced colorectal cancer representing a potential therapeutic target 9
LGALS3BP is a potential target of antibody-drug conjugates in oral squamous cell carcinoma 9
Anti-LGALS3BP antibody-drug conjugate treatment induces durable and potent antitumor response in a preclinical model of adenoid cystic carcinoma 8
Totale 1.575
Categoria #
all - tutte 6.835
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.835


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201927 0 0 0 0 0 0 0 0 0 0 4 23
2019/2020239 45 13 3 4 17 18 33 11 26 38 27 4
2020/2021177 20 3 24 4 10 30 8 4 9 25 8 32
2021/2022175 6 3 4 25 16 11 11 12 17 8 14 48
2022/2023539 43 97 35 65 46 86 20 45 64 12 18 8
2023/2024294 18 10 41 17 18 111 49 12 0 14 4 0
Totale 1.575